DragonFly EU Pivotal Study

Status Not yet recruiting

Clinical Trial Summary

To confirm the effectiveness and safety of the DragonFly Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk subjects and symptomatic moderate-to- severe (3+) or severe (4+) functional mitral regurgitation subjects who remained clinically symptomatic after adequate treatment.

Clinical Trial Description

This is a prospective, multicentric clinical investigation. Subjects to be included in this clinical investigation suffer from symptomatic chronic moderate-to-severe (3+) or severe (4+) DMR with high or prohibitive surgical risk judged by a local investigation site's heart team and symptomatic moderate-to- severe (3+) or severe (4+) functional mitral regurgitation subjects who remained clinically symptomatic after adequate treatment. Local heart teams must include at a minimum a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease. After signing the informed consent form (ICF), a subject will be enrolled and treated with the DragonFlyTM Transcatheter Mitral Valve Repair System (Valgen Medtech, Hangzhou). The CE-DMR cohort clinical investigation will be assessed at the following intervals: implant, before discharge, 30 days, 6 months and annually for 5 years. Group sequential design analysis is planned based on an adaptive design to assess whether the primary endpoint will be met. If the primary endpoint is not met at the interim analysis, then it will be re-analyzed for 160 patients when all subjects in Europe/Canada complete 12 months follow-up. The CE-FMR cohort clinical investigation will be assessed at the following intervals: implant, before discharge, 30 days, 6 months and annually for 5 years. An adaptive design with sample size re-estimation will be incorporated. The primary endpoint will be assessed at the interim analysis. If the conditional power falls within the promising zone (38-80%), then the sample size will be re-estimated to maintain at least 80% power. Then the primary endpoint will be evaluated once the 12-month follow-up is completed with the larger sample size (not less than 165). ;

Study Design

Related Conditions & MeSH terms

Mitral Valve Insufficiency

Clinical Trial Details

NCT number	NCT05927441
Study type	Interventional
Source	Hangzhou Valgen Medtech Co., Ltd
Contact	Shuangjie Li
Phone	+8617756106609
Email	shuangjie.li@valgenmed.com
Status	Not yet recruiting
Phase	N/A
Start date	December 1, 2023
Completion date	May 1, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03962023` - Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)
Withdrawn	`NCT02624960` - Safety and Performance of the AccuCinch® System	N/A
Terminated	`NCT02428010` - Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study	N/A
Active, not recruiting	`NCT01533883` - Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair	N/A
Unknown status	`NCT01201070` - Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery	Phase 4
Terminated	`NCT00700947` - Using Beta Blockers to Treat Mitral Regurgitation	Phase 1
Completed	`NCT04351984` - Transcatheter Mitral Valvuloplasty Pilot Study
Completed	`NCT04231331` - Ertugliflozin for Functional Mitral Regurgitation	Phase 3
Completed	`NCT05742789` - Effect of Anesthetics on Troponin I and С-reactive Protein	Phase 1
Recruiting	`NCT02803957` - Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair	N/A
Recruiting	`NCT04153292` - The ENCIRCLE Trial	N/A
Completed	`NCT02607527` - Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System	N/A
Active, not recruiting	`NCT03066050` - Long Term Follow Up for CTSN Mitral Valve Repair Studies
Active, not recruiting	`NCT04443218` - Edwards PASCAL Transcatheter Valve Repair System Registry
Enrolling by invitation	`NCT04067635` - Primary Mitral Regurgitation Repair
Completed	`NCT01966146` - Examination of Valve Insufficiency Before and After MitraClip or TAVI Procedure by 3D Echocardiography Compared to MRI	N/A
Recruiting	`NCT01368575` - Surgical Treatment of Ischemic Mitral Regurgitation	Phase 4
Completed	`NCT00001314` - Investigation of Heart Function in Patients With Heart Valve Defects	N/A
Terminated	`NCT03285724` - Safety and Performance Study of the Harpoon Mitral Valve Repair System	N/A
Withdrawn	`NCT04709042` - Acquisition of Objective Data During Transapical Neochordae Implantation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.